Sarah Perryman, DO
Rheumatology · Noblesville, INNPI 1023370723
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), speaking fees and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by GSK at 53.3% of the total. 2025 is the largest year on record at $8,709, more than ten times the $124 reported in 2021.
Across 462 payments — averaging $34.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- Amgen$2K
- AbbVie$1K
- Pfizer$812
- Johnson & Johnson$736
- Novartis$687
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$7,15045%
- Travel & lodging$1761%
- Food & beverage$8,25051%
- Education$4813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 58 | $8,564 |
| Amgen(2 entities) | 84 | $1,529 |
| AbbVie | 61 | $1,006 |
| Pfizer | 70 | $812 |
| Johnson & Johnson | 30 | $736 |
| Novartis | 31 | $687 |
| AstraZeneca(2 entities) | 23 | $567 |
| Mallinckrodt Hospital Products Inc. | 23 | $542 |
| UCB, Inc. | 20 | $376 |
| ANI Pharmaceuticals, Inc. | 13 | $186 |
| Organon | 7 | $145 |
| Sanofi | 5 | $144 |
| Lilly USA, LLC | 6 | $107 |
| Fresenius Kabi USA, LLC | 1 | $86 |
| Aurinia Pharma U.S., Inc. | 4 | $77 |
| Boehringer Ingelheim | 4 | $74 |
| Ultragenyx Pharmaceutical Inc. | 3 | $57 |
| Genentech USA, Inc. | 3 | $54 |
| Sobi, Inc | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Celltrion USA Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| LEO Pharma Inc. | 1 | $21 |
| Octapharma USA, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $18 |
| Sandoz | 1 | $16 |
| Biocon Biologics Inc | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Bioventus LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,057 in reported general payments places this provider in the 85th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 35 | $255,116 |
| Orencia ClickjectAbatacept | 40 | $221,049 |
| Enbrel SureclickEtanercept | 29 | $212,401 |
| BenlystaBelimumab | 38 | $182,574 |
| RinvoqUpadacitinib | 21 | $137,949 |
| Cimzia (2 Pack)Certolizumab Pegol | 24 | $134,558 |
| Humira(Cf)Adalimumab | 14 | $101,910 |
| XeljanzTofacitinib Citrate | 13 | $75,818 |
| OrenciaAbatacept | 12 | $69,615 |
| Leflunomide | 201 | $10,403 |
| Hydroxychloroquine Sulfate | 318 | $9,839 |
| RasuvoMethotrexate/Pf | 16 | $9,693 |
| Pilocarpine Hcl | 25 | $1,902 |
| Colchicine | 28 | $1,699 |
| Azathioprine | 12 | $1,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,006 | $239,85935 claims |
| GSKBenlysta | $8,564 | $182,57438 claims |
| UCB, Inc.Cimzia (2 Pack) | $376 | $134,55824 claims |
| PfizerXeljanz | $812 | $75,81813 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $50 | $69,61512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 rheumatology providers in Indiana.
Other rheumatology in Noblesville
- Kathleen ThomasNoblesville$511K
- David BattIndianapolis$577K
- Keith ReichDyer$193K
- Douglas SmithIndianapolis$147K
- Ahmad SalahMerrillville$139K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- Nina RamessarFort Wayne$75K
- Anita ZachariahMunster$37K
- James EhlichIndianapolis$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.